Category Archives: Pr Newswire

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP) Investigators conclude that clinical outcomes of RELIEF-DPN 1 support commencement of Lexicon’s dose-ranging Phase 2b PROGRESS trial, currently enrolling patients THE WOODLANDS, Texas, June 19, 2024 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today […]

LOS ANGELES, June 19, 2024 (GLOBE NEWSWIRE) — Calibre Scientific is pleased to announce the acquisition of DCS Innovative Diagnostik-Systeme GmbH & Co. KG (“DCS” or the “Company”), a German supplier of reagents and equipment used in immunohistochemistry for the diagnostic, research, industrial, university and hospital industries, with a focus on clinical pathology and oncology […]

REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of […]

Patent No. US 11,998,632 B2 (“Patent”) covers Avicanna’s self-emulsifying drug delivery system (“SEDDS”) oral cannabinoid composition and methods of treating neuropathic pain TORONTO, June 19, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is […]

June 19, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 4,437,164 of its shares. The cancelled shares were acquired as part of the completed EUR 1.5 billion share repurchase program for capital reduction purposes that was announced on July 26, 2021. Philips’ current […]

Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study. Golidocitinib monotherapy demonstrated superior and durable clinical benefits and a favorable safety profile in r/r PTCL patients, compared with existing treatment options. SHANGHAI, June 19, 2024 /PRNewswire/ — Dizal (SSE:688192), […]

BEIJING, June 19, 2024 /PRNewswire/ — The “618” Grand Promotion of 2024 has drawn to a close, a landmark event that has ushered in a new era of simplified shopping. This year’s event has eschewed the traditional pre-sales format in favor of an elongated promotional period designed to improve the consumer experience. E-commerce titans—Alibaba, JD, […]

SHANGHAI, June 19, 2024 /PRNewswire/ — GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China’s National Medical Products Administration (NMPA) has approved the clinical trial application for GFH375 (VS-7375) in an open-label, multi-center phase I/II study targeting advanced solid tumor patients with KRAS G12D mutation. G12D mutation is […]

HSINCHU, June 19, 2024 /PRNewswire/ — M31 Technology Corporation (M31), a global provider of silicon intellectual property (IP), announced the launch of the latest LPDDR memory IP solution to meet the growing demand in the high-performance computing (HPC) application market, even looking beyond the computing power to the artificial intelligence (AI) field, where there is […]

HONG KONG and SHANGHAI, June 19, 2024 /PRNewswire/ — The “Ping An Family Doctor Brand Upgrade Conference” was held in Shanghai recently. Ping An Insurance (Group) Company of China, Ltd. (hereafter “Ping An” or the “Group”, HKEX: 2318 / 82318; SSE: 601318) has upgraded its “Ping An Family Doctor” brand with a one-stop, proactive health management […]